EUVIMEDEUVIMED entdecken
Leserbrief

Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia

The Medical Letter on Drugs and Therapeutics · 2025

DOI: 10.58347/tml.2025.1727e ↗

Kurz gefasst

Leserbrief in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2025. Hauptthemen laut MEDLINE: Choline, Diazoxide, Prader-Willi Syndrome, Hyperphagia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved diazoxide choline extended-release tablets (Vykat XR – Soleno Therapeutics) for treatment of hyperphagia in patients ≥4 years old with Prader-Willi syndrome. Diazoxide choline is the first drug to be approved in the US for this indication. Diazoxide oral suspension (Proglycem) has been available for years for management of symptomatic hypoglycemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholineDiazoxidePrader-Willi SyndromeHyperphagiaHumans

Stichwörter der Autor:innen

ProglycemVykatadverse effectsdiazoxidedosagedrug interactionsefficacyhyperphagialactationpregnancysafety

Substanzen

diazoxide cholineCholineDiazoxide

Zitieren

APA

(2025). Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2025.1727e

Vancouver

Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia. The Medical Letter on Drugs and Therapeutics. 2025. doi:10.58347/tml.2025.1727e

BibTeX
@article{euvimed2025,
  title = {Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2025},
  doi = {10.58347/tml.2025.1727e}
}
Kostenlos starten →